Therapy options for metastatic triple negative breast cancer
Open Access
- 19 June 2022
- journal article
- research article
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 201-206
Abstract
Metastatic triple-negative breast cancer remains the most unfavourable among all breast cancer subtypes from the prognostic point of view. Despite the active introduction into practice of combinations of cytostatics with immunotherapeutic agents, as well as PARP inhibitors, sequential lines of chemotherapy with the median overall survival which does not exceed 15 months remains the main method of treating patients in this group. This breast cancer subtype is characterized by a rapid development of drug resistance at the early stages of systemic treatment and a predominantly visceral progression, which determines a low life expectancy in patients. The combination of capecitabine and ixabepilone has proved to be effective in the treatment of tumours that are resistant to taxanes and anthracyclines. The use of this combination is characterized by an acceptable and controlled toxicity profile. This article presents a clinical case of therapy with a combination of ixabepilone and capecitabine of a patient with breast cancer progression during the previous therapy of taxanes, a platinum-based doublet chemotherapy and eribulin. This approach, together with symptomatic laparocentesis and pleurodesis, allowed for overall survival exceeding 45 months with the preservation of a satisfactory functional status of the patient.Keywords
This publication has 20 references indexed in Scilit:
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT TrialNature Medicine, 2018
- Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 2015
- Pleurodesis using different agents in malignant pleural effusionThe Egyptian Journal of Chest Diseases and Tuberculosis, 2012
- Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical TrialsClinical Breast Cancer, 2012
- Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trialsSupportive Care in Cancer, 2012
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial DesignClinical Breast Cancer, 2009
- Pattern of metastatic spread in triple-negative breast cancerBreast Cancer Research and Treatment, 2008
- Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane TreatmentJournal of Clinical Oncology, 2007
- Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and CapecitabineJournal of Clinical Oncology, 2007
- Peripheral Neuropathy Induced by Microtubule-Stabilizing AgentsJournal of Clinical Oncology, 2006